Preclinical News and Research

RSS
Bio-molecules present in human breast milk can help resolve inflammation, combat infection

Bio-molecules present in human breast milk can help resolve inflammation, combat infection

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

enGene, Janssen Biotech sign agreement to develop and commercialize new IBD therapies

enGene, Janssen Biotech sign agreement to develop and commercialize new IBD therapies

CU Cancer Center study reports 'robust antitumor activity' of TAK-733 drug in mouse models of colorectal cancer

CU Cancer Center study reports 'robust antitumor activity' of TAK-733 drug in mouse models of colorectal cancer

MR Solutions launches MRS-PET system that allows simultaneous acquisition of PET and MRI imaging data

MR Solutions launches MRS-PET system that allows simultaneous acquisition of PET and MRI imaging data

Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

Lilly, ImaginAb partner to study potential novel T-cell-based immuno-oncology therapies

Lilly, ImaginAb partner to study potential novel T-cell-based immuno-oncology therapies

ATA announces first-year research grants to support promising young researchers

ATA announces first-year research grants to support promising young researchers

Antiviral agent protects rhesus monkeys from deadly Ebola virus

Antiviral agent protects rhesus monkeys from deadly Ebola virus

Immune-molecule-based mop-up therapy reduces specific type of breast tumor in mice

Immune-molecule-based mop-up therapy reduces specific type of breast tumor in mice

Wake Forest Baptist Medical Center announces creation of Technology Development Program

Wake Forest Baptist Medical Center announces creation of Technology Development Program

Dr. Paul Liu named 2015 Distinguished Alumnus for contributions to leukemia research

Dr. Paul Liu named 2015 Distinguished Alumnus for contributions to leukemia research

Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

Vertera Spine receives FDA 510(k) clearance for COHERE Cervical Interbody Fusion Device

Vertera Spine receives FDA 510(k) clearance for COHERE Cervical Interbody Fusion Device

Envisia's ENV515 (travoprost XR) meets primary efficacy endpoint in phase 2a glaucoma trial

Envisia's ENV515 (travoprost XR) meets primary efficacy endpoint in phase 2a glaucoma trial

Mycobacterium could be more effective in treating superficial bladder cancer, study finds

Mycobacterium could be more effective in treating superficial bladder cancer, study finds

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

Plymouth University and Ingenza partner to develop efficient, scalable microbial production system for epidermicin

Plymouth University and Ingenza partner to develop efficient, scalable microbial production system for epidermicin

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.